<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38535610</PMID><DateRevised><Year>2024</Year><Month>03</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-0817</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Mar</Month><Day>20</Day></PubDate></JournalIssue><Title>Pathogens (Basel, Switzerland)</Title><ISOAbbreviation>Pathogens</ISOAbbreviation></Journal><ArticleTitle>The Course of COVID-19 and Long COVID: Identifying Risk Factors among Patients Suffering from the Disease before and during the Omicron-Dominant Period.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">267</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pathogens13030267</ELocationID><Abstract><AbstractText>SARS-CoV-2 has acquired many mutations that influence the severity of COVID-19's course or the risk of developing long COVID. In 2022, the dominant SARS-CoV-2 variant was Omicron. This study aimed to compare the course of COVID-19 in the periods before and during the dominance of the Omicron variant. Risk factors for developing long COVID were also assessed. This study was based on stationary visits of patients after COVID-19 and follow-up assessments after 3 months. Clinical symptoms, comorbidities, and vaccination status were evaluated in 1967 patients. Of the analyzed group, 1308 patients (66.5%) were affected by COVID-19 in the period before the Omicron dominance. The prevalence of long COVID was significantly lower among patients of the Omicron group (47.7% vs. 66.9%, <i>p</i> &lt; 0.001). The risk of long COVID was higher for women (OR: 1.61; 95% CI: 1.31, 1.99]) and asthmatics (OR: 1.46; 95% CI: 1.03, 2.07]). Conclusively, infection during the Omicron-dominant period was linked to a lower risk of developing long COVID. Females are at higher risk of developing long COVID independent of the pandemic period. Individuals affected by COVID-19 in the Omicron-dominant period experience a shorter duration of symptoms and reduced frequency of symptoms, except for coughing, which occurs more often.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Babicki</LastName><ForeName>Mateusz</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7719-6959</Identifier><AffiliationInfo><Affiliation>Department of Family Medicine, Wroclaw Medical University, 51-141 Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko&#x142;at</LastName><ForeName>Damian</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-1086-3796</Identifier><AffiliationInfo><Affiliation>Department of Biomedicine and Experimental Surgery, Medical University of Lodz, Narutowicza 60, 90-136 Lodz, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Functional Genomics, Medical University of Lodz, &#x17b;eligowskiego 7/9, 90-752 Lodz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ka&#x142;uzi&#x144;ska-Ko&#x142;at</LastName><ForeName>&#x17b;aneta</ForeName><Initials>&#x17b;</Initials><Identifier Source="ORCID">0000-0002-2335-3293</Identifier><AffiliationInfo><Affiliation>Department of Biomedicine and Experimental Surgery, Medical University of Lodz, Narutowicza 60, 90-136 Lodz, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Functional Genomics, Medical University of Lodz, &#x17b;eligowskiego 7/9, 90-752 Lodz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapusta</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5082-3641</Identifier><AffiliationInfo><Affiliation>Department of Internal Diseases, Rehabilitation and Physical Medicine, Medical University of Lodz, 90-647 Lodz, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mastalerz-Migas</LastName><ForeName>Agnieszka</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-6600-2760</Identifier><AffiliationInfo><Affiliation>Department of Family Medicine, Wroclaw Medical University, 51-141 Wroclaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jankowski</LastName><ForeName>Piotr</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-6223-8821</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine and Geriatric Cardiology, Medical Centre for Postgraduate Education, 01-813 Warsaw, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chudzik</LastName><ForeName>Micha&#x142;</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8805-9688</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine and Geriatric Cardiology, Medical Centre for Postgraduate Education, 01-813 Warsaw, Poland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, 90-549 Lodz, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>The Medical Center of Postgraduate Education.</GrantID><Agency>The Medical Center of Postgraduate Education.</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pathogens</MedlineTA><NlmUniqueID>101596317</NlmUniqueID><ISSNLinking>2076-0817</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">pre-Omicron</Keyword><Keyword MajorTopicYN="N">risk factors</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>3</Month><Day>27</Day><Hour>12</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>27</Day><Hour>12</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>27</Day><Hour>9</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>3</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38535610</ArticleId><ArticleId IdType="pmc">PMC10975347</ArticleId><ArticleId IdType="doi">10.3390/pathogens13030267</ArticleId><ArticleId IdType="pii">pathogens13030267</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>WHO COVID-19 Dashboard.  [(accessed on 4 January 2024)].  Available online:  https://covid19.who.int/</Citation></Reference><Reference><Citation>Li J., Huang D.Q., Zou B., Yang H., Hui W.Z., Rui F., Yee N.T.S., Liu C., Nerurkar S.N., Kai J.C.Y., et al. Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes. J. Med. Virol. 2021;93:1449&#x2013;1458. doi: 10.1002/jmv.26424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26424</ArticleId><ArticleId IdType="pmc">PMC7436673</ArticleId><ArticleId IdType="pubmed">32790106</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrowolska K., Brzdek M., Zarebska-Michaluk D., Rzymski P., Rogalska M., Moniuszko-Malinowska A., Szymanek-Pasternak A., Jaroszewicz J., Dutkiewicz E., Kowalska J., et al. Differences between the course of SARS-CoV-2 infections in the periods of the Delta and Omicron variant dominance in Poland. Pol. Arch. Intern. Med. 2023;133 doi: 10.20452/pamw.16403.</Citation><ArticleIdList><ArticleId IdType="doi">10.20452/pamw.16403</ArticleId><ArticleId IdType="pubmed">36602857</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez-Leon S., Wegman-Ostrosky T., Perelman C., Sepulveda R., Rebolledo P.A., Cuapio A., Villapol S. More than 50 long-term effects of COVID-19: A systematic review and meta-analysis. Sci. Rep. 2021;11:16144. doi: 10.1038/s41598-021-95565-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95565-8</ArticleId><ArticleId IdType="pmc">PMC8352980</ArticleId><ArticleId IdType="pubmed">34373540</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C.H., Murray B., Varsavsky T., Graham M.S., Penfold R.S., Bowyer R.C., Pujol J.C., Klaser K., Antonelli M., Canas L.S., et al. Attributes and predictors of long COVID. Nat. Med. 2021;27:626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Babicki M., Kapusta J., Pieniawska-Smiech K., Kaluzinska-Kolat Z., Kolat D., Mastalerz-Migas A., Jankowski P., Chudzik M. Do COVID-19 Vaccinations Affect the Most Common Post-COVID Symptoms? Initial Data from the STOP-COVID Register-12-Month Follow-Up. Viruses. 2023;15:1370. doi: 10.3390/v15061370.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15061370</ArticleId><ArticleId IdType="pmc">PMC10304551</ArticleId><ArticleId IdType="pubmed">37376668</ArticleId></ArticleIdList></Reference><Reference><Citation>Tulimilli S.V., Dallavalasa S., Basavaraju C.G., Kumar Rao V., Chikkahonnaiah P., Madhunapantula S.V., Veeranna R.P. Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. Vaccines. 2022;10:1751. doi: 10.3390/vaccines10101751.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10101751</ArticleId><ArticleId IdType="pmc">PMC9607623</ArticleId><ArticleId IdType="pubmed">36298616</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy A., Pongor S., Gyorffy B. Different mutations in SARS-CoV-2 associate with severe and mild outcome. Int. J. Antimicrob. Agents. 2021;57:106272. doi: 10.1016/j.ijantimicag.2020.106272.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijantimicag.2020.106272</ArticleId><ArticleId IdType="pmc">PMC7755579</ArticleId><ArticleId IdType="pubmed">33347989</ArticleId></ArticleIdList></Reference><Reference><Citation>Rochman N.D., Wolf Y.I., Faure G., Mutz P., Zhang F., Koonin E.V. Ongoing global and regional adaptive evolution of SARS-CoV-2. Proc. Natl. Acad. Sci. USA. 2021;118:2104241118. doi: 10.1073/pnas.2104241118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2104241118</ArticleId><ArticleId IdType="pmc">PMC8307621</ArticleId><ArticleId IdType="pubmed">34292871</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian D., Sun Y., Xu H., Ye Q. The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant. J. Med. Virol. 2022;94:2376&#x2013;2383. doi: 10.1002/jmv.27643.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27643</ArticleId><ArticleId IdType="pmc">PMC9015498</ArticleId><ArticleId IdType="pubmed">35118687</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu F.H., Jia Y.J., Zhao D.Y., Fu X.L., Zhang W.Q., Tang W., Hu S.Q., Wu H., Ge M.W., Du W., et al. Clinical outcomes of the severe acute respiratory syndrome coronavirus 2 Omicron and Delta variant: Systematic review and meta-analysis of 33 studies covering 6 037 144 coronavirus disease 2019-positive patients. Clin. Microbiol. Infect. 2023;29:835&#x2013;844. doi: 10.1016/j.cmi.2023.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2023.03.017</ArticleId><ArticleId IdType="pmc">PMC10023211</ArticleId><ArticleId IdType="pubmed">36934872</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouzid D., Visseaux B., Kassasseya C., Daoud A., Femy F., Hermand C., Truchot J., Beaune S., Javaud N., Peyrony O., et al. Comparison of Patients Infected With Delta Versus Omicron COVID-19 Variants Presenting to Paris Emergency Departments: A Retrospective Cohort Study. Ann. Intern. Med. 2022;175:831&#x2013;837. doi: 10.7326/M22-0308.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M22-0308</ArticleId><ArticleId IdType="pmc">PMC8941485</ArticleId><ArticleId IdType="pubmed">35286147</ArticleId></ArticleIdList></Reference><Reference><Citation>Chatterjee S., Bhattacharya M., Nag S., Dhama K., Chakraborty C. A Detailed Overview of SARS-CoV-2 Omicron: Its Sub-Variants, Mutations and Pathophysiology, Clinical Characteristics, Immunological Landscape, Immune Escape, and Therapies. Viruses. 2023;15:167. doi: 10.3390/v15010167.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15010167</ArticleId><ArticleId IdType="pmc">PMC9866114</ArticleId><ArticleId IdType="pubmed">36680207</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Zhi H., Teng Y. The outbreak of SARS-CoV-2 Omicron lineages, immune escape, and vaccine effectivity. J. Med. Virol. 2023;95:e28138. doi: 10.1002/jmv.28138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28138</ArticleId><ArticleId IdType="pmc">PMC9538491</ArticleId><ArticleId IdType="pubmed">36097349</ArticleId></ArticleIdList></Reference><Reference><Citation>Pather S., Madhi S.A., Cowling B.J., Moss P., Kamil J.P., Ciesek S., Muik A., Tureci O. SARS-CoV-2 Omicron variants: Burden of disease, impact on vaccine effectiveness and need for variant-adapted vaccines. Front. Immunol. 2023;14:1130539. doi: 10.3389/fimmu.2023.1130539.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2023.1130539</ArticleId><ArticleId IdType="pmc">PMC10242031</ArticleId><ArticleId IdType="pubmed">37287979</ArticleId></ArticleIdList></Reference><Reference><Citation>Flisiak R., Zarebska-Michaluk D., Dobrowolska K., Rorat M., Rogalska M., Krynska J.A., Moniuszko-Malinowska A., Czupryna P., Kozielewicz D., Jaroszewicz J., et al. Change in the Clinical Picture of Hospitalized Patients with COVID-19 between the Early and Late Period of Dominance of the Omicron SARS-CoV-2 Variant. J. Clin. Med. 2023;12:5572. doi: 10.3390/jcm12175572.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12175572</ArticleId><ArticleId IdType="pmc">PMC10488127</ArticleId><ArticleId IdType="pubmed">37685639</ArticleId></ArticleIdList></Reference><Reference><Citation>Nyberg T., Ferguson N.M., Nash S.G., Webster H.H., Flaxman S., Andrews N., Hinsley W., Bernal J.L., Kall M., Bhatt S., et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: A cohort study. Lancet. 2022;399:1303&#x2013;1312. doi: 10.1016/S0140-6736(22)00462-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00462-7</ArticleId><ArticleId IdType="pmc">PMC8926413</ArticleId><ArticleId IdType="pubmed">35305296</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyler L., Van Nedervelde E., De Cock D., Mann C., Pien K., Allard S.D., Demuyser T. Surfing the Waves: Differences in Hospitalised COVID-19 Patients across 4 Variant Waves in a Belgian University Hospital. Viruses. 2023;15:618. doi: 10.3390/v15030618.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15030618</ArticleId><ArticleId IdType="pmc">PMC10057609</ArticleId><ArticleId IdType="pubmed">36992327</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanna D., Peltzer C., Kahar P., Parmar M.S. Body Mass Index (BMI): A Screening Tool Analysis. Cureus. 2022;14:e22119. doi: 10.7759/cureus.22119.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.22119</ArticleId><ArticleId IdType="pmc">PMC8920809</ArticleId><ArticleId IdType="pubmed">35308730</ArticleId></ArticleIdList></Reference><Reference><Citation>Babicki M., Kolat D., Kapusta J., Kaluzinska-Kolat Z., Jankowski P., Mastalerz-Migas A., Banach M., Mordaka R., Chudzik M. Prevalence and assessment of risk factors among Polish adults with post-COVID-19 syndrome: A 12-month follow-up study. Pol. Arch. Intern. Med. 2023;133 doi: 10.20452/pamw.16512.</Citation><ArticleIdList><ArticleId IdType="doi">10.20452/pamw.16512</ArticleId><ArticleId IdType="pubmed">37338234</ArticleId></ArticleIdList></Reference><Reference><Citation>Rzymski P., Pokorska-Spiewak M., Jackowska T., Kuchar E., Nitsch-Osuch A., Pawlowska M., Babicki M., Jaroszewicz J., Szenborn L., Wysocki J., et al. Key Considerations during the Transition from the Acute Phase of the COVID-19 Pandemic: A Narrative Review. Vaccines. 2023;11:1502. doi: 10.3390/vaccines11091502.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines11091502</ArticleId><ArticleId IdType="pmc">PMC10537111</ArticleId><ArticleId IdType="pubmed">37766178</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewnard J.A., Hong V.X., Patel M.M., Kahn R., Lipsitch M., Tartof S.Y. Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California. Nat. Med. 2022;28:1933&#x2013;1943. doi: 10.1038/s41591-022-01887-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01887-z</ArticleId><ArticleId IdType="pmc">PMC10208005</ArticleId><ArticleId IdType="pubmed">35675841</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulloa A.C., Buchan S.A., Daneman N., Brown K.A. Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada. JAMA. 2022;327:1286&#x2013;1288. doi: 10.1001/jama.2022.2274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.2274</ArticleId><ArticleId IdType="pmc">PMC8855311</ArticleId><ArticleId IdType="pubmed">35175280</ArticleId></ArticleIdList></Reference><Reference><Citation>Severity of Disease Associated with Omicron Variant as Compared with Delta Variant in Hospitalized Patients with Suspected or Confirmed SARS-CoV-2 Infection.  [(accessed on 4 January 2024)].  Available online:  https://www.who.int/publications/i/item/9789240051829.</Citation></Reference><Reference><Citation>Brandal L.T., MacDonald E., Veneti L., Ravlo T., Lange H., Naseer U., Feruglio S., Bragstad K., Hungnes O., Odeskaug L.E., et al. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. Euro Surveill. 2021;26:2101147. doi: 10.2807/1560-7917.ES.2021.26.50.2101147.</Citation><ArticleIdList><ArticleId IdType="doi">10.2807/1560-7917.ES.2021.26.50.2101147</ArticleId><ArticleId IdType="pmc">PMC8728491</ArticleId><ArticleId IdType="pubmed">34915975</ArticleId></ArticleIdList></Reference><Reference><Citation>Patil B. Omicron: The tsunami? Indian J. Health Sci. Biomed. Res. (KLEU) 2022;15:1. doi: 10.4103/kleuhsj.kleuhsj_76_22.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/kleuhsj.kleuhsj_76_22</ArticleId></ArticleIdList></Reference><Reference><Citation>Das S., Samanta S., Banerjee J., Pal A., Giri B., Kar S.S., Dash S.K. Is Omicron the end of pandemic or start of a new innings? Travel. Med. Infect. Dis. 2022;48:102332. doi: 10.1016/j.tmaid.2022.102332.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmaid.2022.102332</ArticleId><ArticleId IdType="pmc">PMC9033632</ArticleId><ArticleId IdType="pubmed">35472451</ArticleId></ArticleIdList></Reference><Reference><Citation>Monge S., Rojas-Benedicto A., Olmedo C., Mazagatos C., Jose Sierra M., Limia A., Martin-Merino E., Larrauri A., Hernan M.A., on behalf of IBERCovid Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: A nationwide cohort study. Lancet Infect. Dis. 2022;22:1313&#x2013;1320. doi: 10.1016/S1473-3099(22)00292-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00292-4</ArticleId><ArticleId IdType="pmc">PMC9162477</ArticleId><ArticleId IdType="pubmed">35658998</ArticleId></ArticleIdList></Reference><Reference><Citation>COVID-19 Advice for the Public: Getting Vaccinated.  [(accessed on 4 January 2024)].  Available online:  https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines/advice.</Citation></Reference><Reference><Citation>Faust J.S., Du C., Liang C., Mayes K.D., Renton B., Panthagani K., Krumholz H.M. Excess Mortality in Massachusetts During the Delta and Omicron Waves of COVID-19. JAMA. 2022;328:74&#x2013;76. doi: 10.1001/jama.2022.8045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.8045</ArticleId><ArticleId IdType="pmc">PMC9257575</ArticleId><ArticleId IdType="pubmed">35594035</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim A.R., Lee J., Park S., Kang S.W., Lee Y.W., Lim S.Y., Chang E., Bae S., Jung J., Kim M.J., et al. Comparison of the causes of death associated with delta and Omicron SARS-CoV-2 variants infection. J. Infect. Public Health. 2023;16:133&#x2013;135. doi: 10.1016/j.jiph.2022.11.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jiph.2022.11.030</ArticleId><ArticleId IdType="pmc">PMC9710103</ArticleId><ArticleId IdType="pubmed">36516648</ArticleId></ArticleIdList></Reference><Reference><Citation>Relan P., Motaze N.V., Kothari K., Askie L., Le Polain O., Van Kerkhove M.D., Diaz J., Tirupakuzhi Vijayaraghavan B.K. Severity and outcomes of Omicron variant of SARS-CoV-2 compared to Delta variant and severity of Omicron sublineages: A systematic review and metanalysis. BMJ Glob. Health. 2023;8:e012328. doi: 10.1136/bmjgh-2023-012328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjgh-2023-012328</ArticleId><ArticleId IdType="pmc">PMC10347449</ArticleId><ArticleId IdType="pubmed">37419502</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu J., Kim M., Jalal A.T., Goldberg J.E., Acevedo Martinez E.M., Suarez Moscoso N.P., Rubio-Gomez H., Mayer D., Visbal A., Sareli C., et al. Distinct Clinical Presentations and Outcomes of Hospitalized Adults with the SARS-CoV-2 Infection Occurring during the Omicron Variant Surge. Healthcare. 2023;11:1703. doi: 10.3390/healthcare11121703.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare11121703</ArticleId><ArticleId IdType="pmc">PMC10297950</ArticleId><ArticleId IdType="pubmed">37372821</ArticleId></ArticleIdList></Reference><Reference><Citation>Arabi M., Al-Najjar Y., Mhaimeed N., Salameh M.A., Paul P., AlAnni J., Abdelati A.A., Laswi I., Khanjar B., Al-Ali D., et al. Severity of the Omicron SARS-CoV-2 variant compared with the previous lineages: A systematic review. J. Cell Mol. Med. 2023;27:1443&#x2013;1464. doi: 10.1111/jcmm.17747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jcmm.17747</ArticleId><ArticleId IdType="pmc">PMC10243162</ArticleId><ArticleId IdType="pubmed">37203288</ArticleId></ArticleIdList></Reference><Reference><Citation>Poniedzialek B., Rzymski P., Zarebska-Michaluk D., Rogalska M., Rorat M., Czupryna P., Kozielewicz D., Hawro M., Kowalska J., Jaroszewicz J., et al. Short-term exposure to ambient air pollution and COVID-19 severity during SARS-CoV-2 Delta and Omicron waves: A multicenter study. J. Med. Virol. 2023;95:e28962. doi: 10.1002/jmv.28962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.28962</ArticleId><ArticleId IdType="pubmed">37466326</ArticleId></ArticleIdList></Reference><Reference><Citation>Uemura K., Kanata T., Ono S., Michihata N., Yasunaga H. The disease severity of COVID-19 caused by Omicron variants: A brief review. Ann. Clin. Epidemiol. 2023;5:31&#x2013;36. doi: 10.37737/ace.23005.</Citation><ArticleIdList><ArticleId IdType="doi">10.37737/ace.23005</ArticleId><ArticleId IdType="pmc">PMC10944996</ArticleId><ArticleId IdType="pubmed">38505732</ArticleId></ArticleIdList></Reference><Reference><Citation>Fall A., Eldesouki R.E., Sachithanandham J., Morris C.P., Norton J.M., Gaston D.C., Forman M., Abdullah O., Gallagher N., Li M., et al. The displacement of the SARS-CoV-2 variant Delta with Omicron: An investigation of hospital admissions and upper respiratory viral loads. EBioMedicine. 2022;79:104008. doi: 10.1016/j.ebiom.2022.104008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.104008</ArticleId><ArticleId IdType="pmc">PMC9020587</ArticleId><ArticleId IdType="pubmed">35460989</ArticleId></ArticleIdList></Reference><Reference><Citation>DeWitt M.E., Tjaden A.H., Herrington D., Schieffelin J., Gibbs M., Weintraub W.S., Sanders J.W., Edelstein S.L., Partnership C.-C.R. COVID-19 Symptoms by Variant Period in the North Carolina COVID-19 Community Research Partnership, North Carolina, USA. Emerg. Infect. Dis. 2023;29:207&#x2013;211. doi: 10.3201/eid2901.221111.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2901.221111</ArticleId><ArticleId IdType="pmc">PMC9796200</ArticleId><ArticleId IdType="pubmed">36573634</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C., Valdes A.M., Polidori L., Antonelli M., Penamakuri S., Nogal A., Louca P., May A., Figueiredo J.C., Hu C., et al. Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: A prospective observational study from the ZOE COVID Study. Lancet. 2022;399:1618&#x2013;1624. doi: 10.1016/S0140-6736(22)00327-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00327-0</ArticleId><ArticleId IdType="pmc">PMC8989396</ArticleId><ArticleId IdType="pubmed">35397851</ArticleId></ArticleIdList></Reference><Reference><Citation>Vihta K.D., Pouwels K.B., Peto T.E., Pritchard E., House T., Studley R., Rourke E., Cook D., Diamond I., Crook D., et al. Omicron-associated changes in SARS-CoV-2 symptoms in the United Kingdom. Clin. Infect. Dis. 2022;76:e133&#x2013;e141. doi: 10.1093/cid/ciac613.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac613</ArticleId><ArticleId IdType="pmc">PMC9384604</ArticleId><ArticleId IdType="pubmed">35917440</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakakubo S., Kishida N., Okuda K., Kamada K., Iwama M., Suzuki M., Yokota I., Ito Y.M., Nasuhara Y., Boucher R.C., et al. Associations of COVID-19 symptoms with omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: A registry-based observational study. Lancet Infect. Dis. 2023;23:1244&#x2013;1256. doi: 10.1016/S1473-3099(23)00271-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00271-2</ArticleId><ArticleId IdType="pmc">PMC10615696</ArticleId><ArticleId IdType="pubmed">37399831</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang Y.R., Huh J.Y., Oh J.Y., Lee J.H., Lee D., Kwon H.S., Kim T.B., Choi J.C., Cho Y.S., Chung K.F., et al. Clinical Characteristics of Post-COVID-19 Persistent Cough in the Omicron Era. Allergy Asthma Immunol. Res. 2023;15:395&#x2013;405. doi: 10.4168/aair.2023.15.3.395.</Citation><ArticleIdList><ArticleId IdType="doi">10.4168/aair.2023.15.3.395</ArticleId><ArticleId IdType="pmc">PMC10186121</ArticleId><ArticleId IdType="pubmed">37075801</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonelli M., Pujol J.C., Spector T.D., Ourselin S., Steves C.J. Risk of long COVID associated with delta versus omicron variants of SARS-CoV-2. Lancet. 2022;399:2263&#x2013;2264. doi: 10.1016/S0140-6736(22)00941-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00941-2</ArticleId><ArticleId IdType="pmc">PMC9212672</ArticleId><ArticleId IdType="pubmed">35717982</ArticleId></ArticleIdList></Reference><Reference><Citation>Diexer S., Klee B., Gottschick C., Xu C., Broda A., Purschke O., Binder M., Frese T., Girndt M., Hoell J.I., et al. Association between virus variants, vaccination, previous infections, and post-COVID-19 risk. Int. J. Infect. Dis. 2023;136:14&#x2013;21. doi: 10.1016/j.ijid.2023.08.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2023.08.019</ArticleId><ArticleId IdType="pubmed">37634619</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottlieb M., Wang R.C., Yu H., Spatz E.S., Montoy J.C.C., Rodriguez R.M., Chang A.M., Elmore J.G., Hannikainen P.A., Hill M., et al. Severe Fatigue and Persistent Symptoms at 3 Months Following Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Pre-Delta, Delta, and Omicron Time Periods: A Multicenter Prospective Cohort Study. Clin. Infect. Dis. 2023;76:1930&#x2013;1941. doi: 10.1093/cid/ciad045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciad045</ArticleId><ArticleId IdType="pmc">PMC10249989</ArticleId><ArticleId IdType="pubmed">36705268</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai F., Tomasoni D., Falcinella C., Barbanotti D., Castoldi R., Mule G., Augello M., Mondatore D., Allegrini M., Cona A., et al. Female gender is associated with long COVID syndrome: A prospective cohort study. Clin. Microbiol. Infect. 2022;28:611.e9&#x2013;611.e16. doi: 10.1016/j.cmi.2021.11.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.11.002</ArticleId><ArticleId IdType="pmc">PMC8575536</ArticleId><ArticleId IdType="pubmed">34763058</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandez-de-Las-Penas C., Martin-Guerrero J.D., Pellicer-Valero O.J., Navarro-Pardo E., Gomez-Mayordomo V., Cuadrado M.L., Arias-Navalon J.A., Cigaran-Mendez M., Hernandez-Barrera V., Arendt-Nielsen L. Female Sex Is a Risk Factor Associated with Long-Term Post-COVID Related-Symptoms but Not with COVID-19 Symptoms: The LONG-COVID-EXP-CM Multicenter Study. J. Clin. Med. 2022;11:413. doi: 10.3390/jcm11020413.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11020413</ArticleId><ArticleId IdType="pmc">PMC8778106</ArticleId><ArticleId IdType="pubmed">35054108</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolff D., Drewitz K.P., Ulrich A., Siegels D., Deckert S., Sprenger A.A., Kuper P.R., Schmitt J., Munblit D., Apfelbacher C. Allergic diseases as risk factors for Long-COVID symptoms: Systematic review of prospective cohort studies. Clin. Exp. Allergy. 2023;53:1162&#x2013;1176. doi: 10.1111/cea.14391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cea.14391</ArticleId><ArticleId IdType="pubmed">37936547</ArticleId></ArticleIdList></Reference><Reference><Citation>Jassat W., Karim S.S.A., Mudara C., Welch R., Ozougwu L., Groome M.J., Govender N., von Gottberg A., Wolter N., Wolmarans M., et al. Clinical severity of COVID-19 in patients admitted to hospital during the omicron wave in South Africa: A retrospective observational study. Lancet Glob. Health. 2022;10:e961&#x2013;e969. doi: 10.1016/S2214-109X(22)00114-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X(22)00114-0</ArticleId><ArticleId IdType="pmc">PMC9116895</ArticleId><ArticleId IdType="pubmed">35597249</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng B., Abdullahi A., Ferreira I., Goonawardane N., Saito A., Kimura I., Yamasoba D., Gerber P.P., Fatihi S., Rathore S., et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 2022;603:706&#x2013;714. doi: 10.1038/s41586-022-04474-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04474-x</ArticleId><ArticleId IdType="pmc">PMC8942856</ArticleId><ArticleId IdType="pubmed">35104837</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozlov M. Omicron&#x2019;s feeble attack on the lungs could make it less dangerous. Nature. 2022;601:177. doi: 10.1038/d41586-022-00007-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-022-00007-8</ArticleId><ArticleId IdType="pubmed">34987210</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki R., Yamasoba D., Kimura I., Wang L., Kishimoto M., Ito J., Morioka Y., Nao N., Nasser H., Uriu K., et al. Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant. Nature. 2022;603:700&#x2013;705. doi: 10.1038/s41586-022-04462-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04462-1</ArticleId><ArticleId IdType="pmc">PMC8942852</ArticleId><ArticleId IdType="pubmed">35104835</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul P., El-Naas A., Hamad O., Salameh M.A., Mhaimeed N., Laswi I., Abdelati A.A., AlAnni J., Khanjar B., Al-Ali D., et al. Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review. Hum. Vaccin. Immunother. 2023;19:2167410. doi: 10.1080/21645515.2023.2167410.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2023.2167410</ArticleId><ArticleId IdType="pmc">PMC10054360</ArticleId><ArticleId IdType="pubmed">36915960</ArticleId></ArticleIdList></Reference><Reference><Citation>Arabi M., Al-Najjar Y., Sharma O., Kamal I., Javed A., Gohil H.S., Paul P., Al-Khalifa A.M., Laws S., Zakaria D. Role of previous infection with SARS-CoV-2 in protecting against omicron reinfections and severe complications of COVID-19 compared to pre-omicron variants: A systematic review. BMC Infect. Dis. 2023;23:432. doi: 10.1186/s12879-023-08328-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-023-08328-3</ArticleId><ArticleId IdType="pmc">PMC10294418</ArticleId><ArticleId IdType="pubmed">37365490</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte K.I., Catahay J.A., Velasco J.V., Pastrana A., Ver A.T., Pangilinan F.C., Peligro P.J., Casimiro M., Guerrero J.J., Gellaco M.M.L., et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A systematic review. EClinicalMedicine. 2022;53:101624. doi: 10.1016/j.eclinm.2022.101624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101624</ArticleId><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuchida T., Hirose M., Inoue Y., Kunishima H., Otsubo T., Matsuda T. Relationship between changes in symptoms and antibody titers after a single vaccination in patients with Long COVID. J. Med. Virol. 2022;94:3416&#x2013;3420. doi: 10.1002/jmv.27689.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27689</ArticleId><ArticleId IdType="pmc">PMC9088489</ArticleId><ArticleId IdType="pubmed">35238053</ArticleId></ArticleIdList></Reference><Reference><Citation>Peghin M., De Martino M., Palese A., Gerussi V., Bontempo G., Graziano E., Visintini E., D&#x2019;Elia D., Dellai F., Marrella F., et al. Post-COVID-19 syndrome and humoral response association after 1 year in vaccinated and unvaccinated patients. Clin. Microbiol. Infect. 2022;28:1140&#x2013;1148. doi: 10.1016/j.cmi.2022.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.03.016</ArticleId><ArticleId IdType="pmc">PMC8940723</ArticleId><ArticleId IdType="pubmed">35339673</ArticleId></ArticleIdList></Reference><Reference><Citation>Wisnivesky J.P., Govindarajulu U., Bagiella E., Goswami R., Kale M., Campbell K.N., Meliambro K., Chen Z., Aberg J.A., Lin J.J. Association of Vaccination with the Persistence of Post-COVID Symptoms. J. Gen. Intern. Med. 2022;37:1748&#x2013;1753. doi: 10.1007/s11606-022-07465-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-022-07465-w</ArticleId><ArticleId IdType="pmc">PMC8906626</ArticleId><ArticleId IdType="pubmed">35266128</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>